Meeder Asset Management’s Utah Medical Products UTMD Stock Holding History

Meeder Asset Management’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-99	Closed	-$5.54K	–	1019
2025 Q4	$5.54K	Hold	99	–	–	﹤0.01%	781
2025 Q3	$6.23K	Buy	+99	New	+$5.86K	﹤0.01%	630
2025 Q1	–	Sell	-140	Closed	-$8.61K	–	1054
2024 Q4	$8.61K	Buy	+140	New	+$9.05K	﹤0.01%	730
2024 Q2	–	Sell	-91	Closed	-$6.47K	–	997
2024 Q1	$6.47K	Buy	+91	New	+$6.83K	﹤0.01%	608
2020 Q4	–	Sell	-16	Closed	-$1K	–	2231
2020 Q3	$1K	Hold	16	–	–	﹤0.01%	2059
2020 Q2	$1K	Hold	16	–	–	﹤0.01%	1967
2020 Q1	$2K	Hold	16	–	–	﹤0.01%	2120
2019 Q4	$2K	Hold	16	–	–	﹤0.01%	2067
2019 Q3	$2K	Hold	16	–	–	﹤0.01%	1992
2019 Q2	$2K	Buy	16 +1	+7%	+$84	﹤0.01%	1882
2019 Q1	$1K	Buy	15 +1	+7%	+$88	﹤0.01%	1650
2018 Q4	$1K	Hold	14	–	–	﹤0.01%	1657
2018 Q3	$1K	Hold	14	–	–	﹤0.01%	1495
2018 Q2	$1.54K	Hold	14	–	–	﹤0.01%	1448
2018 Q1	$1K	Buy	+14	New	+$1.25K	﹤0.01%	1481

Other funds holding UTMD

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meeder Asset Management's UTMD Position: Q1 2026 in Review

Meeder Asset Management sold out of Utah Medical Products (UTMD) in Q1 2026, closing a stake of 99 shares — an estimated $5.54K sold.

Meeder Asset Management first reported a position in UTMD in Q1 2018 and held it in 15 quarters. The position peaked at $8.61K in Q4 2024. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

Meeder Asset Management reported no remaining Utah Medical Products position as of Q1 2026 after selling out during the quarter.
Meeder Asset Management sold 99 Utah Medical Products shares in Q1 2026, an estimated $5.54K.
Meeder Asset Management first reported a position in Utah Medical Products in Q1 2018 and held it in 15 quarters.
Meeder Asset Management's Utah Medical Products position peaked at $8.61K in Q4 2024.
119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.